This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Research And Markets Announces The Release Of 'Autoimmune Disease Therapeutics To 2016. Targets, Technologies, Therapies, Markets And Opportunities'

DUBLIN, March 20, 2013 /PRNewswire/ --

Dublin - Research and Markets ( http://www.researchandmarkets.com/research/t68g9q/autoimmune) has announced the addition of the "Autoimmune Disease Therapeutics to 2016. Targets, Technologies, Therapies, Markets and Opportunities" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

As a group, autoimmune diseases represent one of the most intractable families of conditions facing medical science. The complexities and genetic underpinnings of the human immune response result in a set of disease targets that are at once physiologically ubiquitous and highly individualized. Until recently, autoimmune disease patients were given little hope for an effective treatment. But the convergence of improved understanding of autoimmune disease mechanisms and the availability of recombinant cytokines has led to systemic treatments that, while not devoid of side effects, have demonstrated the ability to control autoimmune reactions in a significant number of patients. A number of potentially important pipeline drugs hold the promise of future improvements in outcomes for autoimmune disease patients.

This study analyzes current autoimmune therapeutics and assesses the next-generation of candidates and their probable impact on treatment options and the competitive landscape.

Highlights:

- Analyzes current therapeutic options for autoimmune diseases, and evaluates emerging therapeutic candidates and assesses their commercial potential

- Assesses existing and evolving immune disease mechanisms and treatment strategies

- Analyzes more than two dozen existing and emerging autoimmune disease targets and target-specific therapeutic drug products

- Evaluates regional and global opportunities for autoimmune therapeutics

- Provides market data and forecasts for six major autoimmune disease segments to 2016

Topics Covered:

Executive Summary

Autoimmune Therapeutics Segment Dynamics

Sector Market Dynamics Patient Demographics and Growth Chronic Disease and Self-administration Managed Care and Prescribing Trends Factors Limiting Growth Industry Alignment and Competitive Landscape

Autoimmune Therapeutic Market Assessments

Arthritis Disease Forms and Immune Mechanisms Therapeutic Strategies Disease Demographics and Growth Key Approved Therapies Development-stage Candidate Assessment Market Factors Commercial Outlook and Forecasts

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs